ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy

Sakano,Shigeru; Ogawa,Satoshi; Yamamoto,Yoshiaki; Nishijima,Jun; Miyachika,Yoshihiro; Matsumoto,Hiroaki; Hara,Takahiko; Matsuyama,Hideyasu

doi:10.3892/mco.2013.85

ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy

Authors:
- Shigeru Sakano
- Satoshi Ogawa
- Yoshiaki Yamamoto
- Jun Nishijima
- Yoshihiro Miyachika
- Hiroaki Matsumoto
- Takahiko Hara
- Hideyasu Matsuyama
View Affiliations

Affiliations: Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan
Published online on: March 5, 2013 https://doi.org/10.3892/mco.2013.85
Pages: 403-410

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Combined trimodality therapy, including transurethral resection and platinum-based chemoradiotherapy, has shown promising results for muscle-invasive bladder cancer. However, this type of treatment may decrease survival as a result of delayed cystectomy in patients with non‑responding tumors. DNA repair proteins may affect survival of bladder cancer patients receiving combined trimodality therapy, by affecting the perioperative nature of the tumor cells or by repairing DNA damaged by platinum agents and radiation. We investigated the associations of excision repair cross-complementing group 1 (ERCC1), X-ray repair cross-complementing group 1 (XRCC1) and apurinic/apyrimidinic endonuclease 1 (APE1) expression with response and survival in 157 locally advanced bladder cancer patients receiving combined trimodality therapy, in order to determine the predictive value of the expression of these proteins in patient selection for therapy. We examined ERCC1, XRCC1 and APE1 expression in tumor specimens using immunohistochemistry. Patients positive for ERCC1, positive for XRCC1 and positive for either ERCC1 or XRCC1, exhibited significantly improved disease-specific survival rates (P=0.023, 0.025 and 0.0091, respectively). In multivariate analysis, combined ERCC1 and XRCC1 expression was independently associated with disease-specific mortality [risk ratio (RR): 0.64; 95% confidence interval (CI), 0.43‑0.94 and P=0.024]. Thus, combined ERCC1 and XRCC1 expression may serve as an independent prognostic marker for survival in bladder cancer patients receiving combined trimodality therapy. Prospective studies with a larger sample size are required to confirm these results.

View Figures

View References

1.	Rödel C, Grabenbauer GG, Kühn R, et al: Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 20:3061–3071. 2002.PubMed/NCBI
2.	Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 14:119–126. 1996.
3.	Kachnic LA, Kaufman DS, Heney NM, et al: Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 15:1022–1029. 1997.PubMed/NCBI
4.	Dunst J, Rödel C, Zietman A, Schrott KM, Sauer R and Shipley WU: Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol. 20:24–32. 2001. View Article : Google Scholar : PubMed/NCBI
5.	Lee CT, Madii R, Daignault S, et al: Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol. 175:1262–1267. 2006. View Article : Google Scholar
6.	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Metzger R, Bollschweiler E, Hölscher AH and Warnecke-Eberz U: ERCC1: impact in multimodality treatment of upper gastrointestinal cancer. Future Oncol. 6:1735–1749. 2010. View Article : Google Scholar : PubMed/NCBI
9.	Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Sak SC, Harnden P, Johnston CF, Paul AB and Kiltie AE: APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res. 11:6205–6211. 2005. View Article : Google Scholar
11.	Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A and Case LD: Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis. 22:917–922. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Thompson LH and West MG: XRCC1 keeps DNA from getting stranded. Mutat Res. 459:1–18. 2000. View Article : Google Scholar : PubMed/NCBI
13.	Ramana CV, Boldogh I, Izumi T and Mitra S: Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals. Proc Natl Acad Sci USA. 95:5061–5066. 1998. View Article : Google Scholar
14.	Chang-Claude J, Popanda O, Tan XL, et al: Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res. 11:4802–4809. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Jun HJ, Ahn MJ, Kim HS, et al: ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 99:167–172. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Weiss C, Wolze C, Engehausen DG, et al: Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol. 24:2318–2324. 2006. View Article : Google Scholar
17.	Shipley WU, Prout GR Jr, Einstein AB, et al: Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 258:931–935. 1987. View Article : Google Scholar : PubMed/NCBI
18.	Sakano S, Wada T, Matsumoto H, et al: Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer. 95:561–570. 2006. View Article : Google Scholar
19.	Shinohara A, Sakano S, Hinoda Y, et al: Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Sci. 100:2376–2382. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Sakano S, Hinoda Y, Sasaki M, et al: Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics. 11:1377–1387. 2010. View Article : Google Scholar : PubMed/NCBI
21.	Sakano S, Matsumoto H, Yamamoto Y, et al: Association between DNA repair gene polymorphisms and p53 alterations in Japanese patients with muscle-invasive bladder cancer. Pathobiology. 73:295–303. 2006. View Article : Google Scholar : PubMed/NCBI
22.	Mohrenweiser HW, Carrano AV, Fertitta A, et al: Refined mapping of the three DNA repair genes, ERCC1, ERCC2, and XRCC1, on human chromosome 19. Cytogenet Cell Genet. 52:11–14. 1989. View Article : Google Scholar : PubMed/NCBI
23.	Liang J, Jiang T, Yao RY, Liu ZM, Lv HY and Qi WW: The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol. 66:493–500. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Bamias A, Karina M, Papakostas P, et al: A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol. 65:1009–1021. 2010. View Article : Google Scholar
25.	Simon GR, Sharma S, Cantor A, Smith P and Bepler G: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 127:978–983. 2005. View Article : Google Scholar : PubMed/NCBI
26.	Coffey JC, Wang JH, Smith MJ, Bouchier-Hayes D, Cotter TG and Redmond HP: Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 4:760–768. 2003. View Article : Google Scholar : PubMed/NCBI
27.	Sergeant G, Roskams T, van Pelt J, Houtmeyers F, Aerts R and Topal B: Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma. BMC Cancer. 11:472011. View Article : Google Scholar : PubMed/NCBI
28.	De Castro G Jr, Pasini FS, Siqueira SA, et al: ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep. 25:693–699. 2011.PubMed/NCBI
29.	Gazdar AF: DNA repair and survival in lung cancer - the two faces of Janus. N Engl J Med. 356:771–773. 2007. View Article : Google Scholar : PubMed/NCBI
30.	Bellmunt J, Paz-Ares L, Cuello M, et al: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 18:522–528. 2007. View Article : Google Scholar : PubMed/NCBI
31.	Matsumura N, Nakamura Y, Kohjimoto Y, et al: The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. BJU Int. 108:E110–E116. 2011. View Article : Google Scholar
32.	Hoffmann AC, Wild P, Leicht C, et al: MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia. 12:628–636. 2010.PubMed/NCBI
33.	Kawashima A, Nakayama M, Kakuta Y, et al: Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res. 17:2561–2569. 2011. View Article : Google Scholar : PubMed/NCBI
34.	Zhang Y, Rohde LH and Wu H: Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair. Curr Genomics. 10:250–258. 2009. View Article : Google Scholar : PubMed/NCBI
35.	Herrera M, Dominguez G, Garcia JM, et al: Differences in repair of DNA cross-links between lymphocytes and epithelial tumor cells from colon cancer patients measured in vitro with the comet assay. Clin Cancer Res. 15:5466–5472. 2009. View Article : Google Scholar : PubMed/NCBI